BibTex RIS Cite

Gebelik ve malign melanom

Year 2017, Volume: 2 Issue: 1, 14 - 24, 04.05.2017

Abstract

Gebeliğin melanom üzerine  etkisi  olabileceği uzun zamandır tartışılmaktadır. Olgu raporları ve serileri, gebelik sırasında Malign Melanom (MM) tanısı konan kadınlarda prognozun kötü olduğunu bildirmiştir. Ayrıca gebelikteki pigmentasyon değişiklikleri, gebeliğin MM progresyonu üzerine potansiyel negatif etkisi olabileceğini düşündürmektedir. Gebeliğin fizyolojik durumu ile kanser hücrelerinin büyümesini ve toleransını uyarabilecek immünsupresif durum arasında benzerlikler bulunsada immünsupresif durumun melanom gelişimine veya progresyonuna yol açabileceğini gösteren spesifik kanıtlar  mevcut değildir. Mevcut bulguların büyük bir kısmı, MM tanısının gebelikten önce, gebelik sırasında, veya gebelikten sonra konulmasının prognozu etkilemediğini göstermektedir. Gebelik sırasında tanısı konan bazı MM olgularında Breslow kalınlığı artmış olsa da bu durum, tanının gecikmesi sebebiyle  olabilir. Araştırmacıların bir kısmı halen MM  hormona duyarlı malignite olduğunu düşünmekle birlikte oral kontraseptif(OKS) ve Hormon tedavisi kullanımının MM gelişimi ile ilişkili  olmadığı epidemiyolojik çalışmalarla gösterilmiştir. MM hücrelerinde ER-beta reseptörlerinin eksprese edildiği gösterilse de  bu ER-beta ekspresyonunun klinik önemi henüz net değildir. Lokal MM tanısı konan doğurganlık çağındaki kadınların gebe kalması kontrendike değilken, kötü prognostik faktörler mevcutsa bir sonraki gebelik için 3 yıl beklenmesi uygundur. Gebelik ilişkili MM olgularının yönetimi  mevcut   prognostik faktörler  doğrultusunda bireysel olarak planlanmalıdır ve  özel cerrahi yaklaşım gerektirmektedir.

References

  • Bradford PT, Anderson WF, Purdue MP, et al. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomarkers Prev. 2010;19: 2401-2406.
  • Andersson TM, Johansson ALV, Fredriksson I, et al. Cancer during pregnancy and the post-partum period: a population-based study. Cancer. 2015;121:2072-2077.
  • Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control. 2008;19:437-442.
  • Byrd BF Jr, Mc Ganity WJ. The effect of pregnancy on the clinical course of malignant melanoma. South Med J. 1954;47: 196-200
  • Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84:985-1000.
  • Mitov M, Joseph R, Copland J 3rd. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015; 417:94-102.
  • Byrom L, Olsen C, Knight L, et al. Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29: 1457-1466.
  • Betz AG. Tolerating pregnancy. Nature. 2012;490:47-48.
  • Leber A, Teles A, Zenclussen AC. Regulatory T-cells and their role in pregnancy. Am J Reprod Immunol. 2010;63: 445-459.
  • Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol. 2010;116:393-401.
  • Driscoll MS, Martires K, Bieber AK, Pomeranz MK, Grant-Kels JM, Stein JA. Pregnancy and melanoma. J Am Acad Dermatol. 2016 Oct;75(4):669-78.
  • Johansson ALV, Andersson TM, Plym A, et al. Mortality in women with pregnancy-associated melanoma. J Am Acad Dermatol. 2014;71:1093-1101.
  • Daryanani D, Plukker JT, De Hullu JA, et al. Pregnancy and early-stage melanoma. Cancer. 2003;97:2248-2253.
  • Tellez A, Rueda S, Conic RZ, et al. Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age. J Am Acad Dermatol. 2016;74:731-738
  • Lens MB, Rosdahl I, Newton-Bishop J. Cutaneous melanoma during pregnancy: is the controversy over? J Clin Oncol. 2009; 27:11-12.
  • Stensheim H, Moller B, van Dijk T, et al. Cause-specific survival for women diagnosed with cancer during pregnancy and lactation: a registry-based cohort study. J Clin Oncol. 2009;27: 45-51.
  • Matires KJ, Stein JA, Grant-Kels JM, Driscoll MS. Meta-analysis concerning mortality for pregnancy-associated melanoma. J Eur Acad Dermatol Venereol. September 25, 2015. http://dx.doi.org/10.1111/jdv.13349 [Epub ahead of print].
  • Moller H, Purushotham A, Linklater KM, et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. Eur J Cancer. 2013;49:3686-3693.
  • Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with cutaneous malignant melanomas. J Clin Oncol. 2004;22:4369-4375.
  • Reintgen DS, McCarty KS, Vollmer R, et al. Malignant melanoma and pregnancy. Cancer. 1985;55:1340-1344.
  • Fabian M, Toth V, Somlai B, et al. Retrospective analysis of clinicopathologic characteristics of pregnancy associated melanoma. Pathol Oncol Res. 2015;21:1265-1271.
  • Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol. 2010;28:287-292.
  • Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999;81:918-923.
  • Gefeller O, Hassan K, Wille L, et al. Cutaneous malignant melanomas in women and the role of oral contraceptives. Br J Dermatol. 1998;38:122-124.
  • Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women’s Health Initiative randomized trials. J Natl Cancer Inst. 2011;103:1469-1475.
  • Driscoll MS, Grant-Kels JM. Hormones, nevi and melanoma: an approach to the patient. J Am Acad Dermatol. 2007;57: 919-931.
  • Schmidt AN, Nanney LB, Boyd AS, et al. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15:971-980.
  • Zhou JH, Kim KB, Myers JN, et al. Immunohistochemical expression of hormone receptors in melanoma of pregnant women, non- pregnant women, and men. Am J Dermatopathol. 2014;36:74-77
  • Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control.2006;17:11–19.
  • Kaae J, Andersen A, Boyd HA, et al. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol.2007;165:1265-70
  • Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA. Surgical treatment of melanoma in pregnancy: a practical guideline. J Dtsch Dermatol Ges. 2016;14:585-93.
  • Allaert SE , Carlier SP , Weyne LP et al. First trimester anesthesia exposure and fetal outcome. A review . Acta Anaesthesiol Belg 2007 ; 58 : 119 – 23 .
  • Adams M , KA K . Physiological changes in normal pregnancy . In: Gleicher N (ed.): Principles and Practice of Medical Therapy in Pregnancy . Stanford : Appleton & Lange , 1998 : 25 – 40 .
  • Greer I , Hunt BJ . Low molecular weight heparin in pregnancy: current issues . Br J Haematol 2005 ; 128 : 593 – 601 .
  • Imarengiaye CO , Ekwere IT . Acid aspiration prophylaxis and caesarean delivery: time for another close look . J Obstet Gynaecol 2005 ; 25 : 357 – 8 .
  • Liu W , Dowling JP , Murray WK et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas . Arch Dermatol 2006 ; 142 : 1551 – 8 .
  • Frederiksen MC . The new FDA pregnancy labeling requirements for drugs . J Midwifery Womens Health 2011 ; 56 : 303 – 7.
  • Zanotti-Fregonara P, Laforest R , Wallis JW . Fetal radiation döşe from 18 F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR . J Nucl Med 2015 ; 56 : 1218 – 22.
  • Pflugfelder A , Kochs C , Blum A et al. Malignant melanoma S3- guideline “diagnosis, therapy and follow-up of melanoma ”. J Dtsch Dermatol Ges 2013 ; 11 ( Suppl 6 ): 1 – 116 , 1–26.
  • Broer N , Buonocore S , Goldberg C et al. A proposal for the timing of management of patients with melanoma presenting during pregnancy . J Surg Oncol 2012 ; 106 : 36 – 40 .
Year 2017, Volume: 2 Issue: 1, 14 - 24, 04.05.2017

Abstract

References

  • Bradford PT, Anderson WF, Purdue MP, et al. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomarkers Prev. 2010;19: 2401-2406.
  • Andersson TM, Johansson ALV, Fredriksson I, et al. Cancer during pregnancy and the post-partum period: a population-based study. Cancer. 2015;121:2072-2077.
  • Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control. 2008;19:437-442.
  • Byrd BF Jr, Mc Ganity WJ. The effect of pregnancy on the clinical course of malignant melanoma. South Med J. 1954;47: 196-200
  • Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84:985-1000.
  • Mitov M, Joseph R, Copland J 3rd. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015; 417:94-102.
  • Byrom L, Olsen C, Knight L, et al. Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29: 1457-1466.
  • Betz AG. Tolerating pregnancy. Nature. 2012;490:47-48.
  • Leber A, Teles A, Zenclussen AC. Regulatory T-cells and their role in pregnancy. Am J Reprod Immunol. 2010;63: 445-459.
  • Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol. 2010;116:393-401.
  • Driscoll MS, Martires K, Bieber AK, Pomeranz MK, Grant-Kels JM, Stein JA. Pregnancy and melanoma. J Am Acad Dermatol. 2016 Oct;75(4):669-78.
  • Johansson ALV, Andersson TM, Plym A, et al. Mortality in women with pregnancy-associated melanoma. J Am Acad Dermatol. 2014;71:1093-1101.
  • Daryanani D, Plukker JT, De Hullu JA, et al. Pregnancy and early-stage melanoma. Cancer. 2003;97:2248-2253.
  • Tellez A, Rueda S, Conic RZ, et al. Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age. J Am Acad Dermatol. 2016;74:731-738
  • Lens MB, Rosdahl I, Newton-Bishop J. Cutaneous melanoma during pregnancy: is the controversy over? J Clin Oncol. 2009; 27:11-12.
  • Stensheim H, Moller B, van Dijk T, et al. Cause-specific survival for women diagnosed with cancer during pregnancy and lactation: a registry-based cohort study. J Clin Oncol. 2009;27: 45-51.
  • Matires KJ, Stein JA, Grant-Kels JM, Driscoll MS. Meta-analysis concerning mortality for pregnancy-associated melanoma. J Eur Acad Dermatol Venereol. September 25, 2015. http://dx.doi.org/10.1111/jdv.13349 [Epub ahead of print].
  • Moller H, Purushotham A, Linklater KM, et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. Eur J Cancer. 2013;49:3686-3693.
  • Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with cutaneous malignant melanomas. J Clin Oncol. 2004;22:4369-4375.
  • Reintgen DS, McCarty KS, Vollmer R, et al. Malignant melanoma and pregnancy. Cancer. 1985;55:1340-1344.
  • Fabian M, Toth V, Somlai B, et al. Retrospective analysis of clinicopathologic characteristics of pregnancy associated melanoma. Pathol Oncol Res. 2015;21:1265-1271.
  • Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol. 2010;28:287-292.
  • Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999;81:918-923.
  • Gefeller O, Hassan K, Wille L, et al. Cutaneous malignant melanomas in women and the role of oral contraceptives. Br J Dermatol. 1998;38:122-124.
  • Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women’s Health Initiative randomized trials. J Natl Cancer Inst. 2011;103:1469-1475.
  • Driscoll MS, Grant-Kels JM. Hormones, nevi and melanoma: an approach to the patient. J Am Acad Dermatol. 2007;57: 919-931.
  • Schmidt AN, Nanney LB, Boyd AS, et al. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15:971-980.
  • Zhou JH, Kim KB, Myers JN, et al. Immunohistochemical expression of hormone receptors in melanoma of pregnant women, non- pregnant women, and men. Am J Dermatopathol. 2014;36:74-77
  • Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control.2006;17:11–19.
  • Kaae J, Andersen A, Boyd HA, et al. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol.2007;165:1265-70
  • Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA. Surgical treatment of melanoma in pregnancy: a practical guideline. J Dtsch Dermatol Ges. 2016;14:585-93.
  • Allaert SE , Carlier SP , Weyne LP et al. First trimester anesthesia exposure and fetal outcome. A review . Acta Anaesthesiol Belg 2007 ; 58 : 119 – 23 .
  • Adams M , KA K . Physiological changes in normal pregnancy . In: Gleicher N (ed.): Principles and Practice of Medical Therapy in Pregnancy . Stanford : Appleton & Lange , 1998 : 25 – 40 .
  • Greer I , Hunt BJ . Low molecular weight heparin in pregnancy: current issues . Br J Haematol 2005 ; 128 : 593 – 601 .
  • Imarengiaye CO , Ekwere IT . Acid aspiration prophylaxis and caesarean delivery: time for another close look . J Obstet Gynaecol 2005 ; 25 : 357 – 8 .
  • Liu W , Dowling JP , Murray WK et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas . Arch Dermatol 2006 ; 142 : 1551 – 8 .
  • Frederiksen MC . The new FDA pregnancy labeling requirements for drugs . J Midwifery Womens Health 2011 ; 56 : 303 – 7.
  • Zanotti-Fregonara P, Laforest R , Wallis JW . Fetal radiation döşe from 18 F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR . J Nucl Med 2015 ; 56 : 1218 – 22.
  • Pflugfelder A , Kochs C , Blum A et al. Malignant melanoma S3- guideline “diagnosis, therapy and follow-up of melanoma ”. J Dtsch Dermatol Ges 2013 ; 11 ( Suppl 6 ): 1 – 116 , 1–26.
  • Broer N , Buonocore S , Goldberg C et al. A proposal for the timing of management of patients with melanoma presenting during pregnancy . J Surg Oncol 2012 ; 106 : 36 – 40 .
There are 40 citations in total.

Details

Journal Section Güncel Derlemeler
Authors

Serkan Yazıcı

Emel Bülbül Başkan

Publication Date May 4, 2017
Published in Issue Year 2017 Volume: 2 Issue: 1

Cite

APA Yazıcı, S., & Bülbül Başkan, E. (2017). Gebelik ve malign melanom. Güncel Dermatoloji Dergisi, 2(1), 14-24.
AMA Yazıcı S, Bülbül Başkan E. Gebelik ve malign melanom. GDD. May 2017;2(1):14-24.
Chicago Yazıcı, Serkan, and Emel Bülbül Başkan. “Gebelik Ve Malign Melanom”. Güncel Dermatoloji Dergisi 2, no. 1 (May 2017): 14-24.
EndNote Yazıcı S, Bülbül Başkan E (May 1, 2017) Gebelik ve malign melanom. Güncel Dermatoloji Dergisi 2 1 14–24.
IEEE S. Yazıcı and E. Bülbül Başkan, “Gebelik ve malign melanom”, GDD, vol. 2, no. 1, pp. 14–24, 2017.
ISNAD Yazıcı, Serkan - Bülbül Başkan, Emel. “Gebelik Ve Malign Melanom”. Güncel Dermatoloji Dergisi 2/1 (May 2017), 14-24.
JAMA Yazıcı S, Bülbül Başkan E. Gebelik ve malign melanom. GDD. 2017;2:14–24.
MLA Yazıcı, Serkan and Emel Bülbül Başkan. “Gebelik Ve Malign Melanom”. Güncel Dermatoloji Dergisi, vol. 2, no. 1, 2017, pp. 14-24.
Vancouver Yazıcı S, Bülbül Başkan E. Gebelik ve malign melanom. GDD. 2017;2(1):14-2.